Serina Therapeutics (Serina Therapeutics) ROCE % : 697.02% (As of Jun. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Serina Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2023 was 697.02%.

Serina Therapeutics ROCE % Historical Data

The historical data trend for Serina Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics ROCE % Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

ROCE %

-85.68

-281.67

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
ROCE %	-	-191.45	-598.57	697.02

Serina Therapeutics ROCE % Calculation

Serina Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-2.666	/	( ( (1.844 - 0.371)	+	(0.858 - 0.438) )	/ 2 )
	=	-2.666	/	( (1.473	+	0.42)	/ 2 )
	=	-2.666	/	0.9465
	=	-281.67 %

Serina Therapeutics's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	5.496	/	( ( (0.858 - 0.438)	+	(9.739 - 8.582) )	/ 2 )
	=	5.496	/	( ( 0.42	+	1.157 )	/ 2 )
	=	5.496	/	0.7885
	=	697.02 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Serina Therapeutics (AMEX:SER) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Serina Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024